natgillin/translations-raw huggingface dataset:
MabCampath is used to treat patients with chronic lymphocytic leukaemia (CLL), a cancer of the lymphocytes (a type of white blood cell).
Zdravilo MabCampath se uporablja za zdravljenje bolnikov s kronično limfocitno levkemijo (KLL), kar je rak limfocitov (vrsta belih krvnih celic).
If treatment is needed, breast-feeding should be discontinued during treatment and for at least 4 weeks following MabCampath therapy.
Če je zdravljenje potrebno, je treba med zdravljenjem z zdravilom MabCampath in vsaj še 4 tedne po njem dojenje prekiniti.
Premedications
Premedikacija
Preclinical evaluation of alemtuzumab in animals has been limited to the cynomolgus monkey because of the lack of expression of the CD52 antigen on non-primate species.
Predklinično ocenjevanje alemtuzumaba pri živalih je bilo zaradi odsotnosti ekspresije antigena CD52 pri neprimatnih vrstah omejeno le na opice cynomolgus.
Median Age (Years)
Mediana starosti (leta)
The active substance in MabCampath, alemtuzumab, is a monoclonal antibody.
Zdravilna učinkovina zdravila MabCampath, alemtuzumab, je monoklonsko protitelo.
Summary of first-line patient population and outcomes Independent review of response rate and duration MabCampath n=149
Pregled populacije in rezultatov predhodno ne zdravljenih bolnikov Neodvisen pregled stopnje odzivnosti in trajanje MabCampath n=149 Klorambucil n=148 Vrednost P
In the event of serious infection or severe haematological toxicity MabCampath should be interrupted until the event resolves.
V primeru resne okužbe ali hudih hematoloških toksičnih učinkov je treba zdravilo MabCampath prekiniti, dokler zaplet ne mine.
53.4% Not Applicable N=82
53,4 % ni veljavno
However, if acute moderate to severe adverse reactions such as hypotension, rigors, fever, shortness of breath, chills, rashes and bronchospasm (some of which may be due to cytokine release) occur at either the 3 mg or 10 mg dose levels, then those doses should be repeated daily until they are well tolerated before further dose escalation is attempted (see section 4.4).
Če pa se pri 3- ali 10- mg odmerkih pojavijo akutni zmerni do hudi neželeni učinki, kot so hipotenzija, okorelost, zvišana telesna temperatura, težko dihanje, mrzlica, izpuščaji ali bronhospazem (nekateri od njih nastanejo lahko zaradi sproščanja citokinov), je treba odmerek ponavljati vsak dan, dokler ga bolnik ne prenaša dobro; šele potem pride v poštev nadaljnje povečanje odmerka (glejte poglavje 4.4).
The MAH will continue to submit yearly PSURs, unless otherwise specified by the CHMP.
Imetnik dovoljenja za promet z zdravilom bo predložil vsakoletna Periodična poročila o varnosti (PSUR), razen če bo CHMP določil drugače.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Imetnik dovoljenja za promet:
You should stop breast-feeding when you start your treatment and you should not begin breast-feeding again until at least 4 weeks after you have finished your treatment and you have consulted your doctor
Ne začnite znova dojiti prej kot 4 tedne po koncu zdravljenja; pred tem se morate posvetovati s svojim zdravnikom.
Transient grade 3 or 4 thrombocytopenia occurs very commonly during the first 2 weeks of therapy and then begins to improve in most patients.
V prvih dveh tednih zdravljenja se zelo pogosto pojavi prehodna trombocitopenija 3. ali 4. stopnje, ki se pri večini bolnikov kasneje izboljša.
Because of the potential for Transfusion Associated Graft Versus Host Disease (TAGVHD) it is recommended that patients who have been treated with MabCampath receive irradiated blood
Zaradi možnosti pojava s transfuzijo povezane bolezni presadka proti gostitelju, je priporočljivo da bolniki, ki so bili zdravljeni z zdravilom MabCampath dobijo obsevane krvne izdelke.
Data available from three uncontrolled B-CLL studies are summarised in the following table:
Naslednja preglednica povzema podatke treh nekontroliranih študij B-KLL.
ORR was superior in patients with any 11q deletion (87% v 29%; p<0.0001) or sole deletion 13q (91% v 62%; p=0.0087) treated with MabCampath compared to chlorambucil.
Celokupni odziv na zdravljenje je višji pri bolnikih s katerimkoli izbrisom 11q (87 % proti 29 %; p<0,0001) in izključno izbrisom 13q (91 % proti 62 %; p=0,0087), zdravljenih z zdravilom MabCampath v primerjavi z bolniki, zdravljenimi z zdravilom klorambucil.
No studies of the effects of MabCampath on the ability to drive and use machines have been performed.
Študij o vplivu zdravila MabCampath na sposobnost vožnje in upravljanja s stroji niso izvedli.
The doctor will carefully monitor you and decide what are the appropriate amounts of MabCampath to give you during your whole treatment period.
Zdravnik vas bo ves čas zdravljenja natančno nadzoroval in določil za vas primeren odmerek zdravila MabCampath.
In the randomized controlled trial in first line patients (Study 4), patients in the MabCampath arm were tested weekly for CMV using a PCR (polymerase chain reaction) assay from initiation through completion of therapy, and every 2 weeks for the first 2 months following therapy.
V randomiziranem, nadzorovanem kliničnem preskušanju predhodno nezdravljenih (zdravljenje prvega izbora) bolnikov (študija 4) so pri bolnikih, zdravljenimi z zdravilom MabCampath, za ugotavljanje CMV vsak teden uporabljali PCR od začetka do konca zdravljenja ter vsaka dva tedna v prvih dveh mesecih po zdravljenju.
Other medicinal products should not be added to the MabCampath infusion solution or simultaneously infused through the same intravenous line (see section 4.5).
Raztopini zdravila MabCampath za infundiranje se ne sme dodati drugih zdravil; prav tako se drugih zdravil ne sme hkrati infundirati po isti intravenski liniji (glejte poglavje 4.5).
During the first week of treatment, MabCampath should be administered in escalating doses: 3 mg on day 1, 10 mg on day 2 and 30 mg on day 3 assuming that each dose is well tolerated.
Prvi teden zdravljenja je treba odmerke zdravila MabCampath postopoma povečevati: 1. dan 3 mg, 2. dan 10 mg in 3. dan 30 mg, pod pogojem, da bolnik vsak odmerek dobro prenaša.
Transient grade 3 or 4 neutropenia occurs very commonly by weeks 5-8 following initiation of treatment.
V obdobju od 5 - 8 tednov po začetku zdravljenja se zelo pogosto pojavi prehodna nevtropenija 3. ali 4. stopnje.
Lymphocytopenia was the most common treatment-related effect in this species.
Najpogostejši z zdravljenjem povezan učinek je bila pri tej vrsti opic limfocitopenija.
Acute adverse reactions, which may occur during initial dose escalation and some of which may be due to the release of cytokines, include hypotension, chills/rigors, fever, shortness of breath and rashes.
Med akutnimi neželenimi učinki, ki se lahko pojavijo med začetnim stopnjevanjem odmerka (nekateri od njih se pojavijo zaradi sproščanja citokinov), so hipotenzija, mrzlica/okorelost, zvišana telesna temperatura, težko dihanje in izpuščaji.
The safety and efficacy of MabCampath were evaluated in a Phase 3, open-label, randomized comparative trial of first line (previously untreated) Rai stage I-IV B-CLL patients requiring therapy (Study 4).
Ocena varnosti in učinkovitosti zdravila MabCampath je bila narejena pri randomiziranih predhodno nezdravljenih bolnikih s stadijem bolezni po Raiju I-IV B-KLL v 3. fazi, ki potrebujejo zdravljenje (4. študija).
You may experience an allergic or hypersensitivity reaction to MabCampath solution, especially against the protein contained in it, while the infusion is given to you.
Pri infundiranju se lahko pojavi alergična ali preobčutljivostna reakcija na raztopino MabCampath in še posebej na beljakovino, ki jo vsebuje.
• bleeding and inflammation of the gums, blisters on the tongue, nosebleeds
• krvavitev iz dlesni in vnetje dlesni, mehurčki na jeziku, krvavitev iz nosu
CD4 and CD8 T-cell counts begin to rise from weeks 8-12 during treatment and continue to recover for several months following the discontinuation of treatment.
Število celic T CD4 in CD8 začne med zdravljenjem naraščati od 8.
• fever, shivering/chills, sweating, nausea (feeling sick), vomiting, low blood pressure, low white/red blood cell levels, infections including pneumonia and blood poisoning, irritation and/or blistering of the mouth region, low blood platelet levels, tiredness, rash, itching, red raised lesions on the skin, shortness of breath, headache, diarrhoea and loss of appetite.
• zvišana telesna temperatura, drgetanje/mrzlica, znojenje, navzea (občutek slabosti), bruhanje, nizek krvni tlak, nizka raven belih/rdečih krvnih celic, okužbe (tudi pljučnica in zastrupitev krvi), draženje in/ali mehurčki v ustih, majhno število trombocitov, utrujenost, izpuščaj, srbenje, rdečkaste vzbrsti nad ravnjo kože, težko dihanje, glavobol, driska in izguba apetita.
Complete blood counts and platelet counts should be obtained at regular intervals during MabCampath therapy and more frequently in patients who develop cytopenias.
Med zdravljenjem z zdravilom MabCampath je treba v rednih presledkih določati celotno krvno sliko in število trombocitov; določanje mora biti pogostejše pri bolnikih, pri katerih se pojavijo citopenije.
If a severe haematological toxicity develops, MabCampath treatment should be interrupted until the event resolves.
Če se pojavi huda hematološka toksičnost, je treba zdravljenje z zdravilom MabCampath prekiniti, dokler zaplet ne mine.
If particulate matter is present or the concentrate is coloured, then the vial should not be used.
Če so prisotni delci ali je koncentrat obarvan, se viale ne sme uporabiti.
A trend toward improved ORR was observed in patients with 17p deletion treated with MabCampath (64% v 20%; p=0.0805).
Trend povečevanja ORR je mogoče opaziti pri bolnikih z izbrisom 17p, zdravljenih z zdravilom MabCampath (64 % proti 20 %; p=0,0805).
≥ 50% decrease from baseline in patients initiating therapy with a baseline ANC ≤ 250/μl and/or a
≥ 50 % zmanjšanje od začetne vrednosti pri bolnikih z začetnim zdravljenjem, pri katerih je bila na začetku vrednost ANC ≤ 250/μl in/ali število trombocitov ≤ 25,000/μl
Dose modification* ANC < 250/μl and/or platelet count ≤25,000/μl
ANC < 250/μl in/ali število trombocitov ≤ 25,000/μl
No studies have been conducted which specifically address the effect of age on MabCampath disposition and toxicity.
Študij, ki bi specifično proučile vpliv starosti na odstranjevanje in toksičnost zdravila MabCampath, niso izvedli.
After the last 30 mg dose, the median volume of distribution at steady-state was 0.15 l/kg (range: 0.1-0.4 l/kg), indicating that distribution was primarily to the extracellular fluid and plasma compartments.
Po zadnjem 30-mg odmerku je bila mediana volumna porazdelitve v stanju dinamičnega ravnovesja 0,15 l/kg (razpon od 0,1 do 0,4 l/kg).
MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for whom fludarabine combination chemotherapy is not appropriate.
Zdravilo MabCampath je indicirano za zdravljenje bolnikov z B-celično kronično limfocitno levkemijo (B-KLL), za katere kemoterapija s fludarabinom ni primerna.
A slight cumulative effect on the degree of lymphocyte depletion was seen in repeated dose studies compared to single dose studies.
V študijah ponavljajočih odmerkov so v primerjavi s študijami posameznih odmerkov opažali rahel kumulativen učinek na izrazitost izčrpanja limfocitov.
MabCampath pharmacokinetics followed a 2-compartment model and displayed non-linear elimination kinetics.
Farmakokinetika zdravila MabCampath je ustrezala dvoprostorskemu modelu; kinetika izločanja ni bila linearna.
The potential for an increased risk of infection-related complications may exist following treatment with multiple chemotherapeutic or biological agents.
Po zdravljenju z več kemoterapevtiki ali biološkimi zdravili obstaja možnost povečanega tveganja za zaplete, povezane z okužbami.
Lymphoma - like disorder
limfomu podobna bolezen
Males and females of childbearing potential should use effective contraceptive measures during treatment and for 6 months following MabCampath therapy (see sections 4.6 and 5.3).
Moški in ženske v rodni dobi morajo med zdravljenjem z zdravilom MabCampath in še 6 mesecev po njem uporabljati učinkovito kontracepcijo (glejte poglavji 4.6 in 5.3).
Within each frequency grouping, undesirable effects observed during treatment or within 30 days following the completion of treatment with MabCampath are presented in order of decreasing
Neželeni učinki se lahko pojavijo v vsaki skupini (glede na pogostnost) med zdravljenjem ali v 30 dneh po končanem zdravljenju z zdravilom MabCampath.
Metabolism and nutritional disorders: Tumour lysis syndrome with fatal outcome has been reported.
Presnovne in prehranske motnje: poročali so o sindromu razpada tumorja s smrtnim izidom.
Pregnancy MabCampath must not be administered to patients who are pregnant, therefore if you:
Nosečnice ne smejo dobivati zdravila MabCampath, zato morate
Complete remissions were also superior in patients with sole 13q deletion treated with MabCampath (27% v 0%; p=0.0009).
Popolna opustitev je bila prav tako boljša pri bolnikih, zdravljenih z zdravilom MabCampath, z izključnim izbrisom 13q (27 % proti 0 %; p=0,0009).
Males and females of childbearing capacity should use effective contraceptive measures during treatment and for 6 months following MabCampath therapy (see section 5.3).
Moški in ženske v rodni dobi morajo med zdravljenjem z zdravilom MabCampath in še 6 mesecev po njem uporabljati učinkovito kontracepcijo (glejte poglavje 5.3).
• weight loss, dehydration, thirst, swelling of the lower legs, temperature change sensation, low
• hujšanje, dehidracija, žeja, otekanje spodnjih okončin, motnje v zaznavanju temperature, nizke
It is highly recommended that anti-infective prophylaxis (e.g. trimethoprim/sulfamethoxazole 1 tablet twice daily, 3 times weekly, or other prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and an effective oral anti-herpes agent, such as famciclovir, 250 mg twice daily) should be initiated while on therapy and for a minimum of 2 months following completion of treatment with MabCampath or until the CD4+ count has recovered to 200 cells/l or greater, whichever is the later.
Med zdravljenjem je nadvse priporočljivo uvesti protimikrobno zaščito (npr. trimetoprim/sulfametoksazol 1 tableto dvakrat na dan, trikrat na teden, ali drugo zaščito proti pljučnici zaradi Pneumocystis jiroveci (PCP) ter učinkovito peroralno sredstvo proti herpesu, npr. 250 mg famciklovirja dvakrat na dan).
Alemtuzumab is a genetically engineered humanised IgG1 kappa monoclonal antibody specific for a 21-28 kD lymphocyte cell surface glycoprotein (CD52) expressed primarily on the surface of normal and malignant peripheral blood B and T cell lymphocytes.
Alemtuzumab je z genskim inženirstvom pridobljeno humanizirano monoklonsko protitelo IgG1 kapa, specifično za 21-28 kD površinski glikoprotein limfocitov (CD52), izražen predvsem na površini normalnih in malignih limfocitov B in T v periferni krvi.
Median PFS was superior in patients with sole 13q deletion treated with MabCampath (24.4 v 13.0 months; p=0.0170 stratified by Rai Stage).
Srednja vrednost PFS pri bolnikih z izključnim izbrisom 13q je bila boljša, če so bili bolniki zdravljeni z zdravilom MabCampath (24,4 proti 13,0 mesecev; p=0,0170, razvrščeno glede na stadije po Raiju).
Infusion reactions: Serious and sometimes fatal reactions, including bronchospasm, hypoxia, syncope, pulmonary infiltrates, acute respiratory distress syndrome (ARDS), respiratory arrest, myocardial infarction, arrhythmias, acute cardiac insufficiency and cardiac arrest have been observed.
Infuzijske reakcije: Poročali so o resnih in včasih usodnih reakcijah, vključno z bronhospazmom, hipoksijo, sinkopo, pljučnimi infiltrati, akutnim sindromom dihalne stiske (ARDS), zastojem dihanja, miokardnim infarktom, aritmijami, akutnim srčnim popuščanjem in zastojem srca.
Serious side effects, including difficulty in breathing, inflammation of the lungs, extreme shortness of breath, fainting, heart attack, low red blood cell and low blood platelet levels, infections, bleeding in the brain (intracranial haemorrhage) have occurred with fatal outcome.
Pojavili so se resni neželeni učinki, vključno s težkim dihanjem, vnetjem pljuč, izredno kratko sapo, omedlevico, srčnim napadom, zmanjšanjem števila rdečih krvnih celic in zmanjšanjem števila trombocitov v krvi, okužbami, krvavitvijo v možganih (intrakranialna krvavitev), ki so bili usodni.
Alemtuzumab is a genetically engineered humanised IgG1 kappa monoclonal antibody specific for a 21-28 kD lymphocyte cell surface glycoprotein (CD52).
Alemtuzumab je z genskim inženirstvom pridobljeno humaniziranoo monoklonsko protitelo IgG1 kapa, specifično za 21-28 kD površinski glikoprotein limfocitov (CD52).
Nervous system disorders: Intracranial haemorrhage has occurred with fatal outcome, in patients with
Bolezni živčevja: pri bolnikih s trombocitopenijo je prišlo do intrakranialnih krvavitev s smrtnim izidom.
These effects will gradually reduce as treatment is continued.
Med nadaljevanjem zdravljenja se bodo neželeni učinki postopoma zmanjšali.
Approximately 97% of first-line patients experienced adverse reactions; the most commonly reported reactions in first line patients usually occurred in the first week of therapy.
Neželeni učinki so se pojavili pri približno 97 odstotkih predhodno nezdravljenih bolnikov (zdravljenje prvega izbora); najpogosteje so se neželeni učinki pojavili v prvem tednu zdravljenja.
Very common
Pogosto
MabCampath is administered into one of your veins via a drip (see also ‘information intended for
Infundiranje zdravila MabCampath poteka preko infuzijske cevke v eno od vaših ven (glejte tudi informacije namenjene zdravstvenemu osebju).
Very common side effects (seen in at least 1 in every 10 patients treated in clinical trials):
Zelo pogosti neželeni učinki (opazili so jih pri najmanj 1 od 10 bolnikov v kliničnih preskušanjih)
MabCampath should be permanently discontinued if autoimmune anaemia or autoimmune thrombocytopenia appears.
Uporabo zdravila MabCampath je treba trajno prenehati, če pride do pojava avtoimunske anemije ali avtoimunske trombocitopenije.
The most frequent serious adverse reactions are cytopenias, infusion reactions, and
Najpogostejši resni neželeni učinki so citopenije, reakcije zaradi infundiranja in imunosupresija/okužbe.
• high blood pressure, fast or slow heart rate, feeling your heart racing, blood vessel spasm • becoming red in the face, bruising of the skin
• visok krvni tlak, hiter ali počasen srčni utrip, občutek razbijanja srca, žilni spazem
Ongoing clinical assessment should be performed for symptomatic CMV infection during MabCampath treatment and for at least 2 months
Bolnike s simptomatskimi okužbami s CMV je treba med zdravljenjem z zdravilom MabCampath in še vsaj dva meseca po končanem zdravljenju redno klinično spremljati.
Severe anaphylactic and other hypersensitivity reactions
Bolezni imunskega sistema alergijske reakcije hude anafilaktične in druge preobčutljivostne reakcije
The most frequent adverse reactions with MabCampath are: infusion reactions (pyrexia, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnoea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anaemia), infections (CMV viraemia, CMV infection, other infections), gastrointestinal symptoms (nausea, emesis, abdominal pain), and neurological symptoms (insomnia, anxiety).
Najpogostejši neželeni učinki pri zdravilu Mabcampath so: reakcije zaradi infundiranja (zvišana telesna temperatura, mrzlica, hipotenzija, urtikarija, navzeja, izpuščaj, tahikardija, dispneja), citopenije (nevtropenija, limfopenija, trombocitopenija, anemija), okužbe (citomegalovirusna viremija (CMV), okužba s CMV, druge okužbe), prebavni simptomi (navzeja, bruhanje, bolečine v trebuhu) in nevrološki simptomi (nespečnost, tesnobnost).
Previously treated B-CLL patients:
Predhodno zdravljeni bolniki z B-KLL
Infections and infestations: Serious and sometimes fatal viral (e.g. adenovirus, parainfluenza, hepatitis B, progressive multifocal leukoencephalopathy (PML)), bacterial (including tuberculosis and atypical mycobacterioses, nocardiosis), protozoan (e.g. toxoplasma gondii), and fungal (e.g. rhinocerebral mucormycosis) infections, including those due to reactivation of latent infections have occurred during post-marketing surveillance.
Infekcijske in parazitske bolezni: Med postmarketinškim spremljanjem so se pojavile resne in včasih usodne virusne (npr. adenovirusi, parainfluenca, hepatitis B, progresivna multifokalna levkoencefalopatija (PML)), bakterijske (vključno s tuberkulozo in atipičnimi mikobakteriozami, nokardiozo), protozojske (npr. toksoplazma gondii) in glivične okužbe (npr. rinocerebralne mukormikoze), vključno s tistimi, ki so posledica reaktiviranja latentnih okužb.
Each time you are given MabCampath, it will take about 2 hours for all the solution to enter your
Vsakič, ko boste dobili zdravilo MabCampath, vam bo raztopina tekla v kri približno 2 uri.
If more MabCampath is given than recommended
Če ste uporabili večji odmerek zdravila MabCampath, kot bi smeli
• inflammation, irritation and/or tightness of the lungs, throat and/or sinuses, too little oxygen reaching the body organs, coughing, coughing up of blood
• vnetje, draženje in/ali tiščanje v pljučih, grlu in/ali obnosnih votlinah, nezadostna preskrba telesnih organov s kisikom, kašelj, izkašljevanje krvi
Do not use MabCampath after the expiry date (EXP) which is stated on the outer carton and the vial label.
Zdravila MabCampath ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki na viali.
4.7 Effects on ability to drive and use machines No studies on the effects on the ability to drive and use machines have been performed.
Študij o vplivu na sposobnost vožnje in upravljanja s stroji niso izvedli.
Your doctor may give you other medicines or change your dose to help reduce any side effects
Za zmanjšanje morebitnih neželenih učinkov vam bo zdravnik morda predpisal še druga zdravila ali pa vam bo spremenil odmerek (glejte poglavje 2.
During the first week, 3 mg of MabCampath is given on Day 1, then 10 mg on Day 2 and then 30 mg on Day 3, depending on tolerability.
Prvi teden naj dobi bolnik prvi dan 3 mg zdravila MabCampath, nato drugi dan 10 mg in tretji dan 30 mg, odvisno kako bolnik zdravilo prenaša.
Women who are pregnant or trying to become pregnant should not handle
Ženske, ki so noseče ali načrtujejo nosečnost, ne smejo biti v stiku z zdravilom MabCampath.
• pins and needles or burning sensation of the skin
• mravljinčenje in pekoč občutek na koži
• injection site reactions including redness, swelling, pain, bruising, inflammation
• reakcije na mestu infundiranja kot so pordelost, otekanje, bolečina, podplutbe, vnetje
Transient hypotension has occurred in patients receiving MabCampath.
Pri bolnikih, ki so dobivali zdravilo MabCampath, se je pojavljala prehodna hipotenzija.
Your healthcare professional will dispose of medicines no longer required.
O načinu odstranjevanja zdravila, ki ga ne potrebujete več, se posvetujte s farmacevtom.
A positive Coombs test has also been observed.
Poročali so tudi o pozitivnem Coombsovem testu in pojavu bolezni presadka proti gostitelju.
*If the delay between dosing is  7 days, initiate therapy at MabCampath 3 mg and escalate to 10 mg
*Če je bilo zdravljenje prekinjeno  7 dni, je treba zdravljenje z zdravilom MabCampath ponovno začeti z odmerkom 3 mg in ga postopoma povečevati do 10 mg ter nato do 30 mg, če ga bolnik prenaša
Additional reactions include nausea, urticaria, vomiting, fatigue, dyspnoea, headache, pruritus, diarrhoea and bronchospasm.
Med dodatne učinke spadajo slabost, koprivnica, bljuvanje, utrujenost, dispneja, glavoboli, urtikarija, driska in bronhospazem.
Cardiac arrest Myocardial infarction Angina pectoris Atrial fibrillation Arrhythmia supraventricular Sinus bradycardia Supraventricular extrasystoles
Srčne bolezni cianoza srčni zastoj bradikardija miokardni infarkt tahikardija angina pektoris sinusna tahikardija atrijska fibrilacija supraventrikularna aritmija sinusna bradikardija supraventrikularna ekstrasistola